TradeFlare's AI research teams analysed DFTX on 30 market nights between April 29, 2026 and September 18, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 18, 2026 | HOLD | $38.68 | $44.48 / $32.88 | -6.8% | not yet | The technicals are bearish and the risk score is high, suggesting a short-term holding period to reassess. |
| August 28, 2026 | BUY | $43.82 | $50.38 / $37.25 | -7.0% | -6.3% | The positive fundamental and sentiment catalysts, particularly the FDA Breakthrough Therapy Designation, suggest a potential upward trend that may take several weeks to fully materialize. |
| August 27, 2026 | BUY | $43.77 | $50.34 / $37.20 | -13.3% | -17.5% | The positive fundamental and sentiment catalysts require time to be fully priced in by the market. |
| August 26, 2026 | BUY | $44.81 | $52.00 / $38.09 | -11.1% | -16.1% | The positive fundamental and sentiment drivers, particularly the Phase 3 trial results, suggest a runway for upward price movement over several weeks. |
| August 25, 2026 | BUY | $43.27 | $47.60 / $36.78 | -14.1% | -16.0% | The stock is in a neutral market regime, and the technicals are mixed, suggesting a shorter-term trading horizon. |
| August 24, 2026 | BUY | $44.91 | $50.52 / $38.17 | -8.2% | -6.8% | The fundamental and sentiment catalysts suggest a medium-term upward trend, but technicals require confirmation. |
| August 22, 2026 | BUY | $44.91 | — / — | -8.2% | -6.8% | The current technical setup is neutral and lacks a clear directional bias for entry. |
| August 5, 2026 | BUY | $42.32 | $47.08 / $35.53 | -3.6% | -12.4% | The fundamental and sentiment catalysts suggest a longer-term upward trend, but technicals indicate a near-term bounce. |
| July 29, 2026 | BUY | $41.96 | $47.16 / $35.67 | +5.3% | +3.8% | The positive fundamental and sentiment catalysts, coupled with a technical oversold bounce signal, suggest a short-to-medium term upward move. |
| July 22, 2026 | HOLD | $45.08 | — / — | -3.5% | +4.9% | Positive Phase 3 trial results for DT120 ODT. |
| July 21, 2026 | BUY | $42.80 | $48.74 / $36.38 | -6.9% | +2.4% | The positive sentiment and fundamental outlook suggest a potential upward move driven by upcoming catalysts. |
| July 20, 2026 | BUY | $44.29 | $55.36 / $37.60 | -0.3% | +5.8% | The positive fundamental and sentiment drivers suggest a medium-term upward trend. |
| July 16, 2026 | BUY | $45.66 | $57.08 / $38.81 | -2.6% | -0.5% | The bullish technical and fundamental outlook, coupled with positive sentiment, suggests a multi-week upward trend. |
| July 15, 2026 | BUY | $45.98 | $68.97 / $34.49 | -4.4% | -6.3% | The positive Phase 3 data and FDA Breakthrough Therapy Designation suggest a catalyst-driven move that could unfold over several weeks. |
| July 14, 2026 | BUY | $43.65 | $65.48 / $32.74 | -2.0% | -11.0% | The bullish technical setup and positive sentiment suggest a short-to-medium term upward trend. |
| July 13, 2026 | BUY | $47.07 | $60.00 / $39.91 | -1.9% | +3.4% | The technical setup and fundamental catalysts suggest a multi-week upward trend. |
| July 8, 2026 | BUY | $44.48 | $57.82 / $37.81 | +0.8% | -2.0% | The strong bullish technicals and fundamentals suggest a sustained upward move is likely over the coming weeks. |
| July 7, 2026 | BUY Published signal · hit stop -15.0% |
$44.19 | $66.29 / $37.56 | +3.4% | -4.9% | The stock has strong technical and fundamental catalysts that suggest a sustained upward move. |
| July 6, 2026 | BUY | $44.19 | $66.29 / $37.56 | -1.5% | -5.7% | The stock has strong technical and fundamental catalysts that suggest a sustained upward move. |
| July 3, 2026 | BUY | $44.19 | $66.29 / $33.14 | -1.5% | -5.7% | The positive technical momentum and strong sentiment suggest a near-term upward move, while the fundamental catalyst of the lead candidate's development provides a longer-term outlook. |
| July 2, 2026 | BUY | $43.40 | $55.00 / $32.55 | +6.5% | -1.5% | The bullish technical and fundamental outlook suggests a multi-week trend. |
| July 1, 2026 | BUY | $47.04 | $54.85 / $30.89 | +11.6% | +2.5% | The technical setup suggests a strong uptrend that could persist for several weeks, supported by positive sentiment. |
| June 25, 2026 | BUY | $42.13 | $53.00 / $35.81 | -1.3% | -3.6% | The positive Phase 3 results and analyst sentiment suggest a near-term upward move, but the high risk profile warrants a shorter horizon. |
| June 24, 2026 | BUY | $36.18 | $45.23 / $30.75 | +3.0% | +1.9% | The positive sentiment and technical setup suggest a short-to-medium term upward trend. |
| May 15, 2026 | BUY | $21.35 | $25.62 / $18.15 | +7.2% | +13.2% | The stock is consolidating, and a clear catalyst is needed to initiate a trade in this neutral market. |
| May 14, 2026 | BUY | $22.01 | — / — | +6.1% | +15.9% | FDA approval of DT120 ODT for GAD. |
| May 13, 2026 | BUY | $21.16 | — / — | -5.2% | +9.5% | Positive clinical trial results for DT120 ODT. |
| May 11, 2026 | BUY | $22.05 | — / — | -4.3% | +7.2% | FDA Breakthrough Therapy Designation for DT120 ODT for GAD. |
| April 30, 2026 | HOLD | $20.49 | $17.42 / $20.49 | +6.0% | +10.6% | Upcoming Phase III trial readouts for lead candidate DT120 ODT. |
| April 29, 2026 | BUY | $21.27 | $24.46 / $18.08 | +14.3% | +14.6% | The stock is currently consolidating and requires a clear catalyst to break out of its current range. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.